Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2020

01-09-2020 | Coronavirus | Viewpoint

Mechanism of higher risk for COVID-19 in diabetes: a mask to lift

Authors: Chen Fang, Yun Huang, Heming Guo, Yihui Sun, Hui Li, Xuna Bian, Haixia Guan, Ji Hu

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

Purpose

This essay aims to propose suggestions on what we can learn from previous investigations to conduct further studies on the potential mechanisms underlying the effect of diabetes mellitus on COVID-19.

Methods

We reviewed some literature on diabetes and other types of coronavirus infection such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) and made some summaries and comparisons.

Results

Diabetes affect the occurrence and progression of COVID-19.

Conclusions

In-depth and comprehensive exploration of the mechanism of diabetes affecting COVID-19 should be carried out.
Literature
1.
Q. Li, X. Guan, P. Wu et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382(13), 1199–1207 (2020)CrossRef
2.
H. Tu, S. Tu, S. Gao et al. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event. J Infect. 18, S0163–S4453 (2020)
3.
4.
5.
T. Chen, D. Wu, H. Chen et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 368, m1295 (2020)
6.
F. Zhou, T. Yu, R. Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395(10229), 1054–1062 (2020)CrossRef
7.
Q. Shi, X. Zhang, F. Jiang, Diabetic patients with COVID-19, characteristics and outcome—a two-centre, retrospective, case control study. SSRN Electronic Journal (2020)
8.
Y.P. Zhang, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China.chin. J Epidemiol 41(2), 145–151 (2020)
9.
D. Wang, B. Hu, C. Hu et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 323(11), 1061–1069 (2020)CrossRef
10.
X. Yang, Y. Yu, J. Xu et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet 8(5), 475–481 (2020)
11.
M. Letko, A. Marzi, V. Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 5(4), 562–569 (2020)CrossRef
12.
J.-K. Yang, S.-S. Lin, X.-J. Ji, et al., Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 47(3), 193–199 (2010).CrossRef
13.
14.
F.Y. Alqahtani, F.S. Aleanizy, R. Ali El Hadi Mohamed et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect. 147, 1–5 (2018)
15.
C.M. Booth, L.M. Matukas, G.A. Tomlinson et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 289(21), 2801–2809 (2003)CrossRef
16.
M. Cotten, T.T. Lam, S.J. Watson et al. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis 19(5), 736–742 (2013)CrossRef
17.
M.A. Garbati, S.F. Fagbo, V.J. Fang et al. A comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes. PLoS ONE 11(11), e0165978 (2016)CrossRef
18.
J.A. Al-Tawfiq, K. Hinedi, J. Ghandour et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 59(2), 160–165 (2014)CrossRef
19.
F.Y. Alqahtani, F.S. Aleanizy, R. Ali El Hadi Mohamed et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect 147, e35 (2019)CrossRef
20.
K.A. Kulcsar, C.M. Coleman, S.E. Beck et al. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 4(20), e131774 (2019)CrossRef
21.
J.W.M. Chan, C.K. Ng, Y.H. Chan et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 58, 686–689 (2003)CrossRef
22.
F. Wu, S. Zhao, B. Yu et al. A new coronavirus associated with human respiratory disease in China. Nature 579(7798), 265–269 (2020)CrossRef
23.
K. Hodgson, J. Morris, T. Bridson et al. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology 144(2), 171–185 (2015)CrossRef
24.
P. Kumar Nathella, S. Babu, Influence of diabetes mellitus on immunity to human tuberculosis. Immunology 152(1), 13–24 (2017)CrossRef
25.
D. Caldeira, J. Alarcão, A. Vaz-Carneiro et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 345, e4260 (2012)CrossRef
26.
S.H. Hsia, P. Duran, M.L. Lee, M.B. Davidson, Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a Sulfonylurea: A pilot study. J Diabetes 12(1), 91–94 (2020)CrossRef
27.
F. Malik, S.F. Mehdi, H. Ali et al. Is metformin poised for a second career as an antimicrobial. Diabetes Metab Res Rev 34(4), e2975 (2018)CrossRef
28.
J. Tuñón, L. Badimón, M.L. Bochaton-Piallat et al. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res 115(1), 10–19 (2019)CrossRef
29.
H. Roca-Ho, M. Marta Riera, V. Palau et al. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci 18(563), 1–13. (2017)
30.
F.A. Shah, H. Mahmud, T. Gallego-Martin et al. Therapeutic effects of endogenous incretin hormones and exogenous incretin-based medications in sepsis. J Clin Endocrinol Metab 104(11), 5274–5284 (2019)CrossRef
Metadata
Title
Mechanism of higher risk for COVID-19 in diabetes: a mask to lift
Authors
Chen Fang
Yun Huang
Heming Guo
Yihui Sun
Hui Li
Xuna Bian
Haixia Guan
Ji Hu
Publication date
01-09-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02423-0

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue

Original Article

Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism

Original Article

Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors

Original Article

Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase

Meta-Analysis

Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials

Original Article

Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism

Original Article

Association between changes in bioactive osteocalcin and glucose homeostasis after biliopancreatic diversion
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits